Tuesday, October 13, 2026

Less Than Hour Before The NYSE Open, Mid Is Down By 4%

Less Than  Hour Before The NYSE Open, Mid Is Down By 4%

(VIANEWS) - The NYSE opens in less than hour and Mid's pre-market value is already 4.72% down.

Mid's last close was $131.58, 16.96% below its 52-week high of $158.46.

The last session, NYSE ended with Mid (MAA) rising 0.6% to $131.58. NYSE rose 0.31% to $18,312.67, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session.

About Mid

MAA, an S&P 500 company, is a real estate investment trust (REIT) focused on delivering full-cycle and superior investment performance for shareholders through the ownership, management, acquisition, development and redevelopment of quality apartment communities primarily in the Southeast, Southwest and Mid-Atlantic regions of the United States. As of December 31, 2023, MAA had ownership interest in 102,662 apartment units, including communities currently in development, across 16 states and the District of Columbia.

Earnings Per Share

As for profitability, Mid has a trailing twelve months EPS of $4.71.

PE Ratio

Mid has a trailing twelve months price to earnings ratio of 27.94. Meaning, the purchaser of the share is investing $27.94 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.11%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jan 11, 2024, the estimated forward annual dividend rate is 5.88 and the estimated forward annual dividend yield is 4.36%.

Volume

Today's last reported volume for Mid is 741520 which is 44.08% below its average volume of 919645.

More news about Mid (MAA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com